Eli Lilly has announced that its net income on a reported basis rose to $2.24bn for the first quarter (Q1) of 2024, a 67% increase from $1.34bn in the same period of the previous year.
Lilly’s growth drivers, Verzenio and Jardiance, suffer setbacks
Prinston Pharma`s Generic Empagliflozin Receives Tentative Approval in U.S
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.Statistical...
Inventiva to present the results of LEGEND Phase IIa combination trial
??Boehringer's Jardiance now gets CDSCO nod for chronic kidney disease
Boehringer`s aldosterone synthase inhibitor shows promise in CKD trial
Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial
Boehringer Ingelheim said Wednesday that it will take part in the first round of price negotiations with the Centers for Medicare and Medicaid Services for its blockbuster type 2 diabetes drug Jardiance (empagliflozin).